Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 9/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 9/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TYMP | P19971 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14125909 | 0.81 | ADORA2A (0.51) | GSK3BALDH1A1TDP1 | |
| SCHEMBL28406876 | 0.80 | ADORA2A (0.50) | GSK3BALDH1A1TDP1 | |
| SCHEMBL11168017 | 0.78 | FDPS (0.40) | FGFR1FGFR4P2RX7FDPSHDAC6 | |
| SCHEMBL28003435 | 0.78 | FDPS (0.43) | FGFR1FGFR4P2RX7FDPSHDAC6 | |
| SCHEMBL10974937 | 0.75 | P2RX7 (0.40) | FGFR1FGFR4P2RX7FDPSHDAC6 | |
| SCHEMBL7594629 | 0.73 | ACHE (0.41) | FGFR1FGFR4HDAC6ALDH1A1LMNA | |
| SCHEMBL28020916 | 0.72 | P2RX7 (0.64) | FGFR1FGFR4P2RX7FDPSHDAC6 | |
| SCHEMBL24021919 | 0.71 | HPRT1 (0.47) | — | |
| SCHEMBL7448126 | 0.70 | MEN1 (0.53) | FGFR1FGFR4P2RX7FDPSHDAC6 | |
| SCHEMBL7626872 | 0.70 | FDPS (0.41) | FDPSHDAC6ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339188-B2 | Compounds for the treatment of cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-05-24 | — | — | US | disclosed |
| US-20200299321-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299321-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | TP53, MYC, CDC73 | FGFR1 1838/4885FGFR4 1342/4885P2RX7 4661/4885 |
| US-11339188-B2 | Compounds for the treatment of cancer | TP53, MYC, CDC73 | FGFR1 1838/4885FGFR4 1342/4885P2RX7 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.